BRAF/NRASwild-type melanoma, NF1 status and sensitivity to trametinib

Loss of NF1 in Cutaneous Melanoma Is Associated with RAS Activation and MEK Dependence

(2014) Moriah H. Nissan et al.   CANCER RESEARCH

BRAF/NRAS Wild-Type Melanomas Have a High Mutation Load Correlating with Histologic and Molecular Signatures of UV Damage

(2013) V. J. Mar et al.   CLINICAL CANCER RESEARCH

Targeted therapy in melanoma – the role of BRAF, RAS and KIT mutations

(2013) Simone M. Goldinger et al.   EJC SUPPLEMENTS

MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study

(2013) Paolo A Ascierto et al.   LANCET ONCOLOGY

Comparison of responses of human melanoma cell lines to MEK and BRAF inhibitors

(2013) Clare J. Stones et al.   Frontiers in Genetics

Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

(2012) R. Dummer et al.   ANNALS OF ONCOLOGY

A Landscape of Driver Mutations in Melanoma

(2012) Eran Hodis et al.   CELL

Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial

(2012) Gerald S Falchook et al.   LANCET ONCOLOGY

Systematic identification of genomic markers of drug sensitivity in cancer cells

(2012) Mathew J. Garnett et al.   NATURE

Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma

(2012) Keith T. Flaherty et al.   NEW ENGLAND JOURNAL OF MEDICINE

Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma

(2011) Caroline Robert et al.   NEW ENGLAND JOURNAL OF MEDICINE